About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

NGM313

Company: NGM Biopharmaceuticals, Inc
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details

Completed NCT NCT02708576

Phase 1 Study of NGM313 in Healthy Adult Participants

Not yet reported NGM Biopharmaceuticals, Inc 151 participants Est. completion 2017-04 1 site Stand-alone

Other conditions: Obesity
View official trial listing →
Completed NCT NCT03298464

Study of NGM313 in Obese Participants

Not yet reported NGM Biopharmaceuticals, Inc 25 participants Est. completion 2018-07-17 1 site Stand-alone

Other conditions: Obese
View official trial listing →
Terminated NCT NCT04583423

A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)

Not yet reported Merck Sharp & Dohme LLC 183 participants Est. completion 2023-04-13 180 sites

MASH
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT03298464

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.